Product Name
Cytokeratin 17 (KRT17), Monoclonal Antibody
Full Product Name
Anti-Cytokeratin 17 Antibody
Product Synonym Names
Keratin type I cytoskeletal 17; 39.1; Cytokeratin-17; CK-17; Keratin-17; K17
Product Gene Name
anti-KRT17 antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q04695
Specificity
Recognizes endogenous levels of Cytokeratin 17 protein.
Form/Format
Liquid in 0.42% Potassium Phosphate, 0.87% Sodium Chloride, pH 7.3, 30% Glycerol, and 0.01% Sodium Azide.
Immunogen
KLH-conjugated synthetic peptide encompassing a sequence of human Cytokeratin 17. The exact sequence is proprietary.
Preparation and Storage
Shipped at 4 degree C. Upon delivery aliquot and store at -20 degree C for one year. Avoid freeze/thaw cycles.
Other Notes
Small volumes of anti-KRT17 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-KRT17 antibody
Mouse monoclonal to Cytokeratin 17
Applications Tested/Suitable for anti-KRT17 antibody
Western Blot (WB), Immunoprecipitation (IP)
Application Notes for anti-KRT17 antibody
Western Blot: (1/1000 - 1/2000); Immunoprecipitation: (1/50 - 1/200)
Western Blot (WB) of anti-KRT17 antibody
Western blot analysis of Cytokeratin 17 expression in Hela (A), MCF7 (B), 293T (C) whole cell lysates.

Immunoprecipitation (IP) of anti-KRT17 antibody
Immunoprecipitation of Cytokeratin 17 from 0.5mg Hela whole cell extract lysate, using anti-Cytokeratin 17 Antibody.

NCBI/Uniprot data below describe general gene information for KRT17. It may not necessarily be applicable to this product.
NCBI Accession #
Q04695.2
[Other Products]
UniProt Primary Accession #
Q04695
[Other Products]
UniProt Secondary Accession #
Q6IP98; Q8N1P6; A5Z1M9; A5Z1N0; A5Z1N1; A5Z1N2; A6NDV6; A6NKQ2[Other Products]
UniProt Related Accession #
Q04695[Other Products]
Molecular Weight
48,106 Da
NCBI Official Full Name
Keratin, type I cytoskeletal 17
NCBI Official Synonym Full Names
keratin 17
NCBI Official Symbol
KRT17??[Similar Products]
NCBI Official Synonym Symbols
PC; K17; PC2; 39.1; CK-17; PCHC1
??[Similar Products]
NCBI Protein Information
keratin, type I cytoskeletal 17
UniProt Protein Name
Keratin, type I cytoskeletal 17
UniProt Synonym Protein Names
39.1; Cytokeratin-17; CK-17; Keratin-17; K17
UniProt Gene Name
KRT17??[Similar Products]
UniProt Synonym Gene Names
CK-17; K17??[Similar Products]
UniProt Entry Name
K1C17_HUMAN
NCBI Summary for KRT17
This gene encodes the type I intermediate filament chain keratin 17, expressed in nail bed, hair follicle, sebaceous glands, and other epidermal appendages. Mutations in this gene lead to Jackson-Lawler type pachyonychia congenita and steatocystoma multiplex. [provided by RefSeq, Aug 2008]
UniProt Comments for KRT17
K17: a type I cytoskeletal keratin. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. There are two types of cytoskeletal and microfibrillar keratin: type I (acidic; 40-55 kDa) [K9 to K20] and type II (neutral to basic; 56-70 kDa) [K1 to K8]. Both a basic and an acidic keratin are required for filament assembly. Generally associates with K6.
Protein type: Cytoskeletal
Chromosomal Location of Human Ortholog: 17q21.2
Cellular Component: cytoplasm; intermediate filament
Molecular Function: MHC class II protein binding; MHC class II receptor activity; protein binding; structural constituent of cytoskeleton
Biological Process: epidermis development; hair follicle morphogenesis; intermediate filament organization; keratinization; positive regulation of cell growth; positive regulation of hair follicle development; positive regulation of translation; signal transduction
Disease: Pachyonychia Congenita 2; Steatocystoma Multiplex
Research Articles on KRT17
1. Case Report: polycystic kidney disease with steatocystoma multiplex. PKD1 mutations disrupt keratin 17 polymerization.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.